Certuity LLC Has $783,000 Holdings in Amgen Inc. (NASDAQ:AMGN)

Certuity LLC lessened its position in shares of Amgen Inc. (NASDAQ:AMGN) by 26.3% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,003 shares of the medical research company’s stock after selling 1,072 shares during the quarter. Certuity LLC’s holdings in Amgen were worth $783,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. TCV Trust & Wealth Management Inc. boosted its holdings in shares of Amgen by 0.8% during the 4th quarter. TCV Trust & Wealth Management Inc. now owns 57,270 shares of the medical research company’s stock worth $14,927,000 after buying an additional 468 shares in the last quarter. Leavell Investment Management Inc. boosted its holdings in shares of Amgen by 0.8% during the 4th quarter. Leavell Investment Management Inc. now owns 17,892 shares of the medical research company’s stock worth $4,663,000 after buying an additional 136 shares in the last quarter. Fortress Financial Solutions LLC bought a new position in shares of Amgen during the 4th quarter worth approximately $281,000. Augustine Asset Management Inc. boosted its holdings in shares of Amgen by 45.2% during the 4th quarter. Augustine Asset Management Inc. now owns 8,520 shares of the medical research company’s stock worth $2,221,000 after buying an additional 2,653 shares in the last quarter. Finally, JSF Financial LLC boosted its holdings in shares of Amgen by 137.5% during the 4th quarter. JSF Financial LLC now owns 2,593 shares of the medical research company’s stock worth $676,000 after buying an additional 1,501 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on AMGN shares. Truist Financial cut their price target on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a report on Wednesday, January 8th. Piper Sandler Companies reiterated an “overweight” rating and issued a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. StockNews.com cut Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. TD Cowen increased their target price on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, Redburn Partners cut their target price on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $314.09.

Amgen Trading Up 0.6 %

Shares of AMGN opened at $296.66 on Wednesday. The business has a 50-day moving average of $272.59 and a 200 day moving average of $302.50. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The firm has a market cap of $159.46 billion, a P/E ratio of 39.29, a price-to-earnings-growth ratio of 3.01 and a beta of 0.56. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.96 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, research analysts forecast that Amgen Inc. will post 20.59 EPS for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.21%. The ex-dividend date is Friday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s payout ratio is presently 119.21%.

Insider Buying and Selling at Amgen

In other news, EVP Jonathan P. Graham sold 25,045 shares of Amgen stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the sale, the executive vice president now owns 28,987 shares in the company, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.69% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.